ClinicalTrials.gg
RecruitingNCT06345365Updated Apr 10, 2024

MA+AZA Regimen for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML)

A Phase 3 interventional study of mitoxantrone liposome, Ara-Cytarabine and azacitidine and Daunorubicin,Ara-Cytarabine, azacitidine in Acute Myeloid Leukaemia, sponsored by Zhongnan Hospital. Recruiting at 11 sites in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-04-10.

Sponsored by Zhongnan Hospital · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2024; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
154
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 473 studies in Leukemia, Myeloid, Acute with a site in China — 264 open to participants now, 289 under way, 40 of them phase 3. Leukemia, Myeloid, Acute · China.

Planned enrollment
80th of 433
154 · median 50
Started
2024
with 67 others
Phase 3
54 of 473
25 open now
Primary completion
2026-12
later than 134 of 288 live
Registered
293rd of 473
by date

Among the 473 studies in Leukemia, Myeloid, Acute with a site in China, this one is the 80th largest by planned enrollment of the 433 interventional ones that give a count, is one of 68 that started in 2024, is one of 54 in phase 3, reaches primary completion later than 134 of the 288 other live ones, and was the 293rd registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

264 of the 473 studies in Leukemia, Myeloid, Acute with a site in China are open now. Recruiting first, the newest first:

259 more — sign in →

All 264 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 473 studies in Leukemia, Myeloid, Acute with a site in China, or all of them as a file.
02

Study summary

Investigator proposed to apply the new dosage form of mitoxantrone hydrochloride liposomes to the clinical treatment of AML, while combining with cytarabine and azacitidine to form the MA+AZA treatment regimen(Mitoxantrone liposome +Ara-Cytarabine+Azacitidine), which would provide an optimal induction treatment regimen for patients with primary AML by comparing with the traditional chemotherapy regimen, DA+AZA (Daunorubicin+Ara-Cytarabine+Azacitidine).

Read the detailed description

In this study, AML patients were randomly divided into MA+AZA treatment group and DA+AZA treatment group by conducting a prospective, multicentre, exploratory, randomised controlled study. By observing the efficacy and safety of the MA+AZA combination regimen in the treatment of primary AML, and comparing the superiority of the traditional regimen, high-quality clinical evidence was obtained, providing practical evidence to support the improvement of the intervention effect and clinical prognosis of primary AML.

03

Conditions studied

  • Acute Myeloid Leukaemia

Keywords

  • Mitoxantrone liposome
  • Newly diagnosed AML patients
  • Ara-Cytarabine
  • Azacytidine
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with primary AML with morphologically and immunologically confirmed diagnosis of bone marrow;
  2. Age 18-75 years old;
  3. Liver and renal function: serum total ≤1.5 × (ULN), /ALT \<2 × ULN, serum creatinine \<1.5 × ULN, 80 ml/min ≤ ≤120 ml/min;
  4. Cardiac function: EF ≥50%, ultrasensitive troponin and natriuretic peptide \<1.5 × ULN;
  5. Physical condition: score 0-2;
  6. Obtained signed by the patient or family.

Exclusion criteria

Exclusion Criteria:

  1. Allergy or significant to any of the drugs involved in the protocol;
  2. Patients with concomitant myelofibrosis;
  3. Severe cardiac disease, including myocardial infarction and cardiac insufficiency;
  4. Concomitant malignant tumours of other organs;
  5. Patients with active tuberculosis and -positive patients;
  6. Other blood system diseases at the same time;
  7. Pregnant or breastfeeding women;
  8. Inability to understand or comply with the study protocol;
  9. Previous intolerance or allergy to similar drugs;
  10. Concurrent participation in other clinical studies;
  11. Any other condition that prevents the study from proceeding.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
154 participants (estimated)

Study arms

  • Experimental
    mitoxantrone liposome, Ara-Cytarabine and azacitidine

    Mitoxantrone hydrochloride liposome 24 mg/m2, IV every 4 weeks, day 1; Ara-Cytarabine 100 mg/m2, IV every 12 h, days 1-7; Azacitidine 100 mg, subcutaneous, once daily, days 1 to 7;

    Drug: mitoxantrone liposome, Ara-Cytarabine and azacitidine

  • Active comparator
    Daunorubicin, Ara-Cytarabine and azacitidine

    Daunorubicin 60 mg/m2, intravenously, once daily, days 1 to 3 Ara-Cytarabine 100 mg/m2, IV drip, every 12h, days 1 to 7; Azacitidine 100 mg, subcutaneous, once daily, days 1 to 7;

    Drug: Daunorubicin,Ara-Cytarabine, azacitidine

Interventions

  • Drugmitoxantrone liposome, Ara-Cytarabine and azacitidine

    Mitoxantrone hydrochloride liposome 24 mg/m2, IV every 4 weeks, day 1; Ara-Cytarabine 100 mg/m2, IV every 12 h, days 1-7; Azacitidine 100 mg, subcutaneous, once daily, days 1 to 7

  • DrugDaunorubicin,Ara-Cytarabine, azacitidine

    Daunorubicin 60 mg/m2, intravenously, once daily, days 1 to 3; Ara-Cytarabine 100 mg/m2, IV drip, every 12h, days 1 to 7; Azacitidine 100 mg, subcutaneous, once daily, days 1 to 7;

06

What researchers measure

Primary outcomes

  1. Complete remission rate

    Bone marrow primitive cells \<5%, no primitive cells with Auer vesicles, no primitive cells in the peripheral blood, no extramedullary leukaemia, neutrophil count ≥1.0×109/L, platelet count ≥100×109/L.

    Time frame: Efficacy evaluation at 2-3 weeks after the first cycle (each cycle is 28 days)

Secondary outcomes

  1. Incidence of adverse events

    Incidence of adverse events, e.g., GI adverse reactions, cardiotoxicity, etc.

    Time frame: Efficacy evaluation at 2-3 weeks after the first cycle (each cycle is 28 days)

  2. Compound CR rate

    CR+ CRi

    Time frame: Efficacy evaluation at 2-3 weeks after the first cycle (each cycle is 28 days)

  3. Objective remission rate

    CR+CRi+MLFS+PR

    Time frame: Efficacy evaluation at 2-3 weeks after the first cycle (each cycle is 28 days)

  4. No remission rate

    Patients not meeting criteria for CR, CRi, MLFS or PR

    Time frame: Efficacy evaluation at 2-3 weeks after the first cycle (each cycle is 28 days)

  5. Event-free survival

    From the date of the patient's first dose to the date of treatment failure,haematological relapse after CR/CRi or all-cause mortality, whichever occurs first

    Time frame: Assessment of up to 100 months from the date of randomisation to the date of first recorded progress or the date of death from any caus)

  6. Disease-free survival

    For patients achieving CR or CRi only, from the date of achieving remission to the date of relapse or death from any cause

    Time frame: From date of achieving remission to date of relapse or death from any cause (Assessment of up to 100 months from the date of randomisation to the date of first recorded progress or the date of death from any cause, whichever comes first)

  7. Overall survival

    The time from the patient's first dose of medication to the time of death from any cause.

    Time frame: Time from the patient's first dose of medication to death from any cause (Assessment of up to 100 months from the date of randomisation to the date of first recorded progress or the date of death from any cause, whichever comes first)

  8. Mortality rate

    Early deaths: all-cause deaths within the timeframe associated with study treatment (e.g., 30 days, 60 days after starting treatment); Cumulative deaths: deaths within the period from the date of achieving remission to the date of no prior relapse for patients achieving CR or CRi only.

    Time frame: 30 days, 60 days after starting treatment; Assessment of up to 100 months from the date of randomisation to the date of first recorded progress or the date of death from any cause, whichever comes first

07

Study locations

1 of 11 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2024 (actual). Primary completion is estimated for Dec 2026, 35 months after the start.

Of 78 non-industry phase 3 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 87 months of starting (the median), counting those still running; a quarter within 66 and three quarters within 111. This study's planned 35 months is below that.

Counting every sponsor, half of 121 studies reached it within 74 months; a quarter within 39 and three quarters within 99.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 1, 2024
First posted
Apr 3, 2024
StartActual
Jan 18, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2028
Last update
Apr 10, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 10, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06345365
Lead sponsor
Zhongnan Hospital
Collaborators
Ruijin Hospital, Shanxi Province Cancer Hospital, The First Affiliated Hospital of Zhengzhou University, Jingzhou Central Hospital, Yichang Central People's Hospital, Taihe Hospital, Central Hospital of Xiaogan, Xianning Central Hospital, The First People's Hospital of Jingzhou
Responsible party
Sponsor
First posted
Apr 3, 2024
Start date
Jan 18, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Apr 10, 2024

Study contacts

Fuling Zhou, Doctor
Contact
zhoufuling@whu.edu.cn
027-67813137
Fuling Zhou
study director · Wuhan University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion